{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T08:54:10Z","timestamp":1780649650225,"version":"3.54.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi di Roma La Sapienza"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Cardiac abnormalities are common in patients with acromegaly, contributing to the increased morbidity and mortality. Cardiac magnetic resonance (CMR) is the gold standard for measuring cardiac morpho-functional changes. This study aims to detect cardiac alterations in acromegaly through CMR, even when the disease is adequately controlled.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this, multicentre, case-control study, we compared consecutive patients with acromegaly, cured after surgery or requiring medical treatment, with matched controls recruited among patients harbouring non-functioning adrenal incidentalomas.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We included 20 patients with acromegaly (7 females, mean age 50 years) and 17 controls. Indexed left ventricular-end-diastolic volume (LV-EDVi) and LV-end-systolic volume (LV-ESVi) were higher in patients than in controls (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), as were left ventricular mass (LVMi) (<jats:italic>p<\/jats:italic>\u2009=\u20090.001) and LV-stroke volume (LV-SVi) (<jats:italic>p<\/jats:italic>\u2009=\u20090.028). Right ventricle (RV) EDVi and ESVi were higher, whereas RV-ejection fraction (RV-EF) was lower (<jats:italic>p<\/jats:italic>\u2009=\u20090.002) in patients than in controls (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). No significant differences were observed in the prevalence of cardiometabolic comorbidities, including hypertension, glucose and lipid metabolism impairment, obstructive sleep apnoea syndrome, and obesity. IGF1 x upper limit of normal significantly predicted LVMi (b\u2009=\u20090.575; <jats:italic>p<\/jats:italic>\u2009=\u20090.008). Subgroup analysis showed higher LVMi (<jats:italic>p<\/jats:italic>\u2009=\u20090.025) and interventricular septum thickness (<jats:italic>p<\/jats:italic>\u2009=\u20090.003) in male than female patients, even after adjusting cardiac parameters for confounding factors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The CMR analysis reveals a cluster of biventricular structural and functional impairment in acromegaly, even when the biochemical control if achieved. These findings appear specifically triggered by the exposure to GH-IGF1 excess and show sex-related differences advocating a possible interaction with sex hormones in cardiac disease progression.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11102-024-01403-1","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T05:01:47Z","timestamp":1717736507000},"page":"416-427","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The spectrum of cardiac abnormalities in patients with acromegaly: results from a case-control cardiac magnetic resonance study"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5242-1761","authenticated-orcid":false,"given":"Dario","family":"De Alcubierre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1066-0064","authenticated-orcid":false,"given":"Tiziana","family":"Feola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8614-5873","authenticated-orcid":false,"given":"Alessia","family":"Cozzolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7808-5735","authenticated-orcid":false,"given":"Riccardo","family":"Pofi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4708-5120","authenticated-orcid":false,"given":"Nicola","family":"Galea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4208-9691","authenticated-orcid":false,"given":"Carlo","family":"Catalano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata Simona","family":"Auriemma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Pirchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9632-1348","authenticated-orcid":false,"given":"Rosario","family":"Pivonello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9037-5417","authenticated-orcid":false,"given":"Andrea M.","family":"Isidori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3614-6151","authenticated-orcid":false,"given":"Elisa","family":"Giannetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,7]]},"reference":[{"issue":"1","key":"1403_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41572-019-0071-6","volume":"5","author":"A Colao","year":"2019","unstructured":"Colao A et al (2019) Acromegaly Nat Rev Dis Primers 5(1):20. https:\/\/doi.org\/10.1038\/s41572-019-0071-6","journal-title":"Acromegaly Nat Rev Dis Primers"},{"issue":"1","key":"1403_CR2","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1210\/er.2002-0022","volume":"25","author":"A Colao","year":"2004","unstructured":"Colao A et al (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25(1):102\u2013152. https:\/\/doi.org\/10.1210\/er.2002-0022","journal-title":"Endocr Rev"},{"issue":"1","key":"1403_CR3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s11102-017-0797-7","volume":"20","author":"R Pivonello","year":"2017","unstructured":"Pivonello R et al (2017) Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities. Pituitary 20(1):46\u201362. https:\/\/doi.org\/10.1007\/s11102-017-0797-7","journal-title":"Pituitary"},{"issue":"11","key":"1403_CR4","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.3275\/8717","volume":"35","author":"G Lombardi","year":"2012","unstructured":"Lombardi G et al (2012) The cardiovascular system in growth hormone excess and growth hormone deficiency. J Endocrinol Invest 35(11):1021\u20131029. https:\/\/doi.org\/10.3275\/8717","journal-title":"J Endocrinol Invest"},{"issue":"15","key":"1403_CR5","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1093\/eurheartj\/ehab822","volume":"43","author":"S Hong","year":"2022","unstructured":"Hong S et al (2022) Acromegaly and cardiovascular outcomes: a cohort study. Eur Heart J 43(15):1491\u20131499. https:\/\/doi.org\/10.1093\/eurheartj\/ehab822","journal-title":"Eur Heart J"},{"issue":"2","key":"1403_CR6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1046\/j.1365-2265.2001.01218.x","volume":"54","author":"A Colao","year":"2001","unstructured":"Colao A et al (2001) Growth hormone and the heart. Clin Endocrinol (Oxf) 54(2):137\u2013154. https:\/\/doi.org\/10.1046\/j.1365-2265.2001.01218.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"1403_CR7","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s42000-020-00235-5","volume":"20","author":"F Ceccato","year":"2021","unstructured":"Ceccato F et al (2021) Clinical presentation and management of acromegaly in elderly patients. Horm (Athens) 20(1):143\u2013150. https:\/\/doi.org\/10.1007\/s42000-020-00235-5","journal-title":"Horm (Athens)"},{"issue":"4","key":"1403_CR8","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1210\/jcem.86.4.7376","volume":"86","author":"A Colao","year":"2001","unstructured":"Colao A et al (2001) Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance. J Clin Endocrinol Metab 86(4):1551\u20131557. https:\/\/doi.org\/10.1210\/jcem.86.4.7376","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1403_CR9","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1046\/j.1365-2265.2001.01343.x","volume":"55","author":"G Minniti","year":"2001","unstructured":"Minniti G et al (2001) Marked improvement in cardiovascular function after successful transsphenoidal surgery in acromegalic patients. Clin Endocrinol (Oxf) 55(3):307\u2013313. https:\/\/doi.org\/10.1046\/j.1365-2265.2001.01343.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"1403_CR10","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1093\/ejendo\/lvad105","volume":"189","author":"P Wolf","year":"2023","unstructured":"Wolf P et al (2023) Increase in intracellular and extracellular myocardial mass in patients with acromegaly: a cardiac magnetic resonance imaging study. Eur J Endocrinol 189(2):199\u2013207. https:\/\/doi.org\/10.1093\/ejendo\/lvad105","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"1403_CR11","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/j.1540-8175.2010.01179.x","volume":"27","author":"E Akgul","year":"2010","unstructured":"Akgul E et al (2010) Evaluation of the impact of treatment on endothelial function and cardiac performance in acromegaly. Echocardiography 27(8):990\u2013996. https:\/\/doi.org\/10.1111\/j.1540-8175.2010.01179.x","journal-title":"Echocardiography"},{"issue":"2","key":"1403_CR12","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1530\/eje.0.1480193","volume":"148","author":"ML Jaffrain-Rea","year":"2003","unstructured":"Jaffrain-Rea ML et al (2003) Impact of successful transsphenoidal surgery on cardiovascular risk factors in acromegaly. Eur J Endocrinol 148(2):193\u2013201. https:\/\/doi.org\/10.1530\/eje.0.1480193","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"1403_CR13","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1530\/EJE-20-0497","volume":"183","author":"A Cozzolino","year":"2020","unstructured":"Cozzolino A et al (2020) Metabolic complications in acromegaly after neurosurgery: a meta-analysis. Eur J Endocrinol 183(6):597\u2013606. https:\/\/doi.org\/10.1530\/EJE-20-0497","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"1403_CR14","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1210\/jc.2018-02281","volume":"104","author":"T Feola","year":"2019","unstructured":"Feola T et al (2019) Pegvisomant improves glucose metabolism in Acromegaly: a Meta-analysis of prospective interventional studies. J Clin Endocrinol Metab 104(7):2892\u20132902. https:\/\/doi.org\/10.1210\/jc.2018-02281","journal-title":"J Clin Endocrinol Metab"},{"key":"1403_CR15","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-02566","author":"A Cozzolino","year":"2018","unstructured":"Cozzolino A et al (2018) Somatostatin analogs and glucose metabolism in Acromegaly: a Meta-analysis of prospective interventional studies. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/jc.2017-02566","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"1403_CR16","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1210\/jc.2014-2700","volume":"99","author":"L Katznelson","year":"2014","unstructured":"Katznelson L et al (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933\u20133951. https:\/\/doi.org\/10.1210\/jc.2014-2700","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"1403_CR17","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1210\/jc.2009-2670","volume":"95","author":"A Giustina","year":"2010","unstructured":"Giustina A et al (2010) A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95(7):3141\u20133148. https:\/\/doi.org\/10.1210\/jc.2009-2670","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1403_CR18","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1093\/ejendo\/lvad066","volume":"189","author":"M Fassnacht","year":"2023","unstructured":"Fassnacht M et al (2023) European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the study of adrenal tumors. Eur J Endocrinol 189(1):G1. https:\/\/doi.org\/10.1093\/ejendo\/lvad066","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"1403_CR19","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.jcmg.2020.10.009","volume":"14","author":"R Pofi","year":"2021","unstructured":"Pofi R et al (2021) Diabetic Cardiomiopathy Progression is triggered by miR122-5p and involves Extracellular Matrix: a 5-Year prospective study. JACC Cardiovasc Imaging 14(6):1130\u20131142. https:\/\/doi.org\/10.1016\/j.jcmg.2020.10.009","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1","key":"1403_CR20","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/1532-429X-15-92","volume":"15","author":"JC Moon","year":"2013","unstructured":"Moon JC et al (2013) Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson 15(1):92. https:\/\/doi.org\/10.1186\/1532-429X-15-92","journal-title":"J Cardiovasc Magn Reson"},{"issue":"9","key":"1403_CR21","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","volume":"14","author":"S Melmed","year":"2018","unstructured":"Melmed S et al (2018) A Consensus Statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol 14(9):552\u2013561. https:\/\/doi.org\/10.1038\/s41574-018-0058-5","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"1403_CR22","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1080\/10976640600572889","volume":"8","author":"AM Maceira","year":"2006","unstructured":"Maceira AM et al (2006) Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson 8(3):417\u2013426. https:\/\/doi.org\/10.1080\/10976640600572889","journal-title":"J Cardiovasc Magn Reson"},{"issue":"2","key":"1403_CR23","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s12968-016-0308-4","volume":"9","author":"R Janardhanan","year":"2011","unstructured":"Janardhanan, R. and C.M. Kramer (2011) Imaging in hypertensive heart disease. Expert Rev Cardiovasc Ther 9(2): p. 199-209. https:\/\/doi.org\/10.1586\/erc.10.190","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"1","key":"1403_CR24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12968-016-0308-4","volume":"18","author":"P Haaf","year":"2016","unstructured":"Haaf P et al (2016) Cardiac T1 mapping and extracellular volume (ECV) in clinical practice: a comprehensive review. J Cardiovasc Magn Reson 18(1):89. https:\/\/doi.org\/10.1186\/s12968-016-0308-4","journal-title":"J Cardiovasc Magn Reson"},{"issue":"1","key":"1403_CR25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/s0002-9149(02)02381-0","volume":"90","author":"F Grothues","year":"2002","unstructured":"Grothues F et al (2002) Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol 90(1):29\u201334. https:\/\/doi.org\/10.1016\/s0002-9149(02)02381-0","journal-title":"Am J Cardiol"},{"issue":"3","key":"1403_CR26","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1365-2265.2007.03047.x","volume":"68","author":"F Bogazzi","year":"2008","unstructured":"Bogazzi F et al (2008) High prevalence of cardiac hypertophy without detectable signs of fibrosis in patients with untreated active acromegaly: an in vivo study using magnetic resonance imaging. Clin Endocrinol (Oxf) 68(3):361\u2013368. https:\/\/doi.org\/10.1111\/j.1365-2265.2007.03047.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"1403_CR27","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.2214\/AJR.07.2031","volume":"190","author":"H Gouya","year":"2008","unstructured":"Gouya H et al (2008) Rapidly reversible myocardial edema in patients with acromegaly: assessment with ultrafast T2 mapping in a single-breath-hold MRI sequence. AJR Am J Roentgenol 190(6):1576\u20131582. https:\/\/doi.org\/10.2214\/AJR.07.2031","journal-title":"AJR Am J Roentgenol"},{"issue":"4","key":"1403_CR28","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s11102-010-0240-9","volume":"13","author":"M Andreassen","year":"2010","unstructured":"Andreassen M et al (2010) Cardiac effects of 3 months treatment of acromegaly evaluated by magnetic resonance imaging and B-type natriuretic peptides. Pituitary 13(4):329\u2013336. https:\/\/doi.org\/10.1007\/s11102-010-0240-9","journal-title":"Pituitary"},{"issue":"12","key":"1403_CR29","doi-asserted-by":"publisher","first-page":"4447","DOI":"10.1210\/jc.2015-2675","volume":"100","author":"CM dos Santos Silva","year":"2015","unstructured":"dos Santos Silva CM et al (2015) Low frequency of Cardiomyopathy using Cardiac magnetic resonance imaging in an Acromegaly Contemporary Cohort. J Clin Endocrinol Metab 100(12):4447\u20134455. https:\/\/doi.org\/10.1210\/jc.2015-2675","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1403_CR30","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1007\/s11102-016-0749-7","volume":"19","author":"L Warszawski","year":"2016","unstructured":"Warszawski L et al (2016) Low frequency of cardniac arrhythmias and lack of structural heart disease in medically-naive acromegaly patients: a prospective study at baseline and after 1 year of somatostatin analogs treatment. Pituitary 19(6):582\u2013589. https:\/\/doi.org\/10.1007\/s11102-016-0749-7","journal-title":"Pituitary"},{"key":"1403_CR31","doi-asserted-by":"publisher","first-page":"p2018464","DOI":"10.1155\/2020\/2018464","volume":"2020","author":"X Guo","year":"2020","unstructured":"Guo X et al (2020) Cardiac abnormalities in Acromegaly patients: a Cardiac magnetic resonance study. Int J Endocrinol 2020:p2018464. https:\/\/doi.org\/10.1155\/2020\/2018464","journal-title":"Int J Endocrinol"},{"issue":"12","key":"1403_CR32","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.jacc.2018.12.076","volume":"73","author":"J Sanz","year":"2019","unstructured":"Sanz J et al (2019) Anatomy, function, and dysfunction of the right ventricle: JACC state-of-the-art review. J Am Coll Cardiol 73(12):1463\u20131482. https:\/\/doi.org\/10.1016\/j.jacc.2018.12.076","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1403_CR33","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s10741-019-09824-y","volume":"25","author":"A De Bellis","year":"2020","unstructured":"De Bellis A et al (2020) Gender-related differences in heart failure: beyond the one-size-fits-all paradigm. Heart Fail Rev 25(2):245\u2013255. https:\/\/doi.org\/10.1007\/s10741-019-09824-y","journal-title":"Heart Fail Rev"},{"issue":"649","key":"1403_CR34","doi-asserted-by":"publisher","first-page":"eabl8503","DOI":"10.1126\/scitranslmed.abl8503","volume":"14","author":"R Pofi","year":"2022","unstructured":"Pofi R et al (2022) Sex-specific effects of daily tadalafil on diabetic heart kinetics in RECOGITO, a randomized, double-blind, placebo-controlled trial. Sci Transl Med 14(649):eabl8503. https:\/\/doi.org\/10.1126\/scitranslmed.abl8503","journal-title":"Sci Transl Med"},{"issue":"24","key":"1403_CR35","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.2174\/0929867324666161118121647","volume":"24","author":"D Gianfrilli","year":"2017","unstructured":"Gianfrilli D et al (2017) The woman\u2019s heart: insights into new potential targeted therapy. Curr Med Chem 24(24):2650\u20132660. https:\/\/doi.org\/10.2174\/0929867324666161118121647","journal-title":"Curr Med Chem"},{"issue":"6","key":"1403_CR36","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1111\/andr.12876","volume":"8","author":"F Sesti","year":"2020","unstructured":"Sesti F et al (2020) Late-onset hypogonadism: Reductio ad absurdum of the cardiovascular risk-benefit of testosterone replacement therapy. Andrology 8(6):1614\u20131627. https:\/\/doi.org\/10.1111\/andr.12876","journal-title":"Andrology"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-024-01403-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-024-01403-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-024-01403-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T13:18:24Z","timestamp":1722345504000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-024-01403-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,7]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1403"],"URL":"https:\/\/doi.org\/10.1007\/s11102-024-01403-1","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,7]]},"assertion":[{"value":"11 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol was reviewed and approved by the Ethical Committee of Policlinico Umberto I, approval number 4244.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients provided written informed consent to participate after receiving a full explanation of the purpose and nature of all procedures used in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"RPi has received research support to Universit\u00e0 Federico II di Napoli as a principal investigator for clinical trials from Novartis Pharma, Recordati, Strongbridge Biopharma, Corcept Therapeutics, HRA Pharma, Shire, Takeda, Neurocrine Biosciences, Camurus AB, and Pfizer, has received research support to Universit\u00e0 Federico II di Napoli from Pfizer, Ipsen, Novartis Pharma, Strongbridge Biopharma, Merk Serono, and Ibsa, and received occasional consulting honoraria from Novartis Pharma, Recordati, Strongbridge Biopharma, HRA Pharma, Crinetics Pharmaceuticals, Corcept Therapeutics, Pfizer, and Bresmed Health Solutions. AMI has served as a consultant for Novartis, Takeda, Recordati, and Sandoz companies, has received unconditional research grants from Shire, IPSEN, and Pfizer. All the other authors have nothing to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}